Sacituzumab for ovarian clear cell cancer after immunotherapy
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a targeted therapy called Sacituzumab for people with a rare type of ovarian cancer (clear cell carcinoma) whose cancer worsened after immunotherapy. The drug is designed to deliver chemotherapy directly to cancer cells, and researchers want to see if it can help when other treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with ovarian clear cell carcinoma (a rare type of ovarian cancer).
- You must have already tried immunotherapy (like Keytruda or Tecentriq) and your cancer got worse after that.
- You must have at least one tumor that can be measured on a scan.
- Your kidneys and liver must be working well, and your blood counts must be normal.
- You must be well enough to carry out daily activities (ECOG score 0 or 1).
- You must not have taken more than 2 other cancer treatments after immunotherapy failed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a new drug (sacituzumab tirumotecan) with or without pembrolizumab for ovarian clear cell cancer that has returned or spread. It's for people who have already had chemotherapy and one type of immunotherapy.
This trial tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) for women whose ovarian cancer stopped responding to platinum chemotherapy. The goal is to see if the combination helps shrink or slow the cancer.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.